Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat controversial.
Novocure received a long-sought FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small ...
From my colleague Adam Feuerstein: The FDA yesterday expanded the approval of Novocure’s Optune electrical ... with the entire health care system.
FDA approves NovoCure's Optune Lua for metastatic non-small cell lung cancer after platinum-based regimen. Optune Lua, combined with immunotherapy or docetaxel, extends overall survival by 3.3 months.
Novocure Ltd (NASDAQ:NVCR) shares soared sharply after the announcement that the FDA had approved Optune Lua, a wearable ...
On October 15th, NovoCure Limited received FDA approval of its lung cancer treatment, which resulted in positive price action. The lung cancer market will significantly increase NovoCure's scale ...
Piper Sandler analyst Jason Bednar maintained a Buy rating on NovoCure (NVCR – Research Report) today and set a price target of $28.00.
Shares of Novocure were trading higher in Tuesday's late session after the company said that the Food and Drug Administration had approved Optune Lua, its wearable treatment for certain types of lung ...
Novocure shares are surging 35% after the company said that the Food and Drug Administration had approved Optune Lua, its wearable treatment for certain types of lung cancer. Interactive Brokers ...
On Tuesday, the FDA approved NovoCure’s (NASDAQ:NVCR) Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel for adult patients with metastatic non-small cell lung cancer (mNSCLC ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...